Effect of Astragalus complanatus flavonoid on anti-liver fibrosis

World Journal of Gastroenterology

Volumn 11, Issue 37, 2005, Pages 5782-5786

  Liu, Chun Yu ^a   Gu, Zhen Lun ^b   Zhou, Wen Xuan ^c   Guo, Ci Yi ^c  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c Hong Kong Association for Health Care Ltd   (Hong Kong)

Author keywords

Astragalus complanatus; Liver fibrosis; Malondialdehyde; Matrix metal protease 1; N propeptide of type I procollagen; N propeptide of type III procollagen; Superoxide dismutase; Tissue inhibitor of metal protease 1

Indexed keywords

ANTIFIBROTIC AGENT; ASTRAGALUS COMPLANATUS EXTRACT; COLCHICINE; DIMETHYLNITROSAMINE; FLAVONOID; INTERSTITIAL COLLAGENASE; MALONALDEHYDE; MESSENGER RNA; PLANT EXTRACT; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTRAGALUS COMPLANATUS; ASTRAGALUS PLANT; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIVER FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 27944457240     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i37.5782     Document Type: Article

References (33)

1. Liu CY, Gu ZL, Han R, Zu LJ, Zhou WX, Guo CY. Protective effect of extract in seed of Astragalus complanatus on acute hepatic injury induced by carbon tetrachloride in mice. Zhongcaoyao 2002; 33: 1104-1106
2. Liu CY, Gu ZL, Zhang KP, Zhou WX, Guo CY. Effect of flavonoids of astragali complanali on liver libroses induced by DMN in rats. Zhonggu Yaolixue Tongbao 2004; 20: 110-114
3. Li ZJ, Jin SHG. Effect of Traditional Chinese Herb Panax Notogenseng (Burk) F.H. Chen on dimethylnitrosamine-induced liver injury in rats. Chengdu Zhongyiyao Daxue Xuebao 2000; 23: 31-35
4. Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D. Elavated serum aminoerminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis. J Hepatol 1996; 25: 79-84
5. Annoni G, Colombo M, Cantaluppi MC, Khlat B, Lampertico P, Rojkind M. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers. Hepatology 1989; 9: 639-697
6. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-563
7. Senoo H. Structure and function of hepatic stellate cells. Med Electron Microsc 2004; 37: 3-15
8. Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed 2002; 4: 27
9. Marra F, Pinzani M. Role of hepatic stellate cells in the pathogenesis of portal hypertension. Nefrologia 2002; 22(Suppl 5): 34-40
10. Reeves HL, Friedman SL. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 2002; 7: 808-826
11. Zhang X, Yu WP, Gaol, Wei KB, Ju JL, Xu JZ. Effects of lipopolysaecharides stimulated Kupffer cells on activation of rat hepatic stellate cells. World J Gastroenterol 2004; 15: 610-613
12. Poli G. Pathogenesis of liver fibrosis role of oxidative stress. Mol Aspects Med 2000; 21: 49-98
13. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306
14. Gebhardt R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 2002; 68: 289-296
15. Refik Mas M, Comert B, Oncu K, Vural SA, Akay C, Tasci I, Ozkomur E, Serdar M, Mas N, Alcigir G, Yener N. The effect of taurine treatment on oxidative stress in experimental liver fibrosis. Hepatol Res 2004; 28: 207-215
16. Xie SB, Yao JL, Zheng RQ, Peng XM, Gao ZL. Serum hyaluronic acid, procollagen type III and IV in histological diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int 2003; 2: 69-72
17. Stone PJ. Potential use of collagen and elastin degradation markers for monitoring liver fibrosis in schistosomiasis. Acta Trop 2000; 77: 97-99
18. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001; 3: 12-18
19. McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol 2000; 15: 1159-1168
20. Okazaki I, Watanabe T, Hozawa S, Arai M, Maruyama K. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases. J Gastroenterol Hepatol 2000; 15(Suppl 1): D26-32
21. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373-384
22. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21: 351-372
23. Okazaki I, Arai M, Wada N, Maruyama K. Gene expression of MMPS and TIMPS in the process of hepatic fibrosis. Nippon Rinsho 1993; 51: 428-434
24. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069-11076
25. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: 245-249
26. Arthur MJ, Iredale JP, Mann DA. Tissue inhibitors of metalloproteinase: role in liver fibrosis and alcoholic liver disease. Alcohol Clin Exp Res 1999; 23: 940-943
27. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997; 29: 43-54
28. Murphy F, Arthur M, Iredale J. Developing strategies for liver fibrosis treatment. Expert Opin Investig Drugs 2002; 11: 1575-1585
29. Shimizu I. Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord 2001; 1: 227-240
30. 14-induced liver fibrosis in rats. World J Gastroenterol 2004; 10: 1037-1042
31. Stickel F, Brinkhaus B, Krahmer N, Seitz HK, Hahn EG, Schuppan D. Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology 2002; 49: 1102-1108
32. Tang WX, Dan ZL, Yan HM, Wu CH, Zhang G, Liu M, Li Q, Li SB. Experimental study of effect of Ganyanping on fibrosis in rat livers. World J Gastroenterol 2003; 9: 1292-1295
33. Du B, You S. Present situation in preventing and treating liver fibrosis with TCM drugs. J Tradit Chin Med 2001; 21: 147-152